Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Revenue projections:

Revenue projections for VRTX
Revenue projections for VRTX

Vertex Pharmaceuticals Incorporated's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 3.185000
forwardPE 24.210985
debtToEquity 9.767000
earningsGrowth 0.080000
revenueGrowth 0.125000
grossMargins 0.549570
operatingMargins 0.380550
trailingEps 17.170000
forwardEps 21.816130

Vertex Pharmaceuticals Incorporated's current ratio of 3.185 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, Vertex Pharmaceuticals Incorporated can comfortably cover its liabilities, reflecting a strong financial outlook.
VRTX's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
VRTX's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
VRTX's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that VRTX is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for VRTX
Price projections for VRTX

Price projections for Vertex Pharmaceuticals Incorporated have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for Vertex Pharmaceuticals Incorporated's growth and market performance.

Insider Transactions:

Insider Transactions for VRTX
Insider Transactions for VRTX


32 sales transactions of Vertex Pharmaceuticals Incorporated were conducted, with market price at 460.4465618133545.VRTX saw 1 transactions to buy shares, with a market price of 385.6499938964844.No distinct trend emerges from insider transactions, leaving uncertainty about whether these actions indicate a positive or negative outlook for the company.

Recommendation changes over time:

Recommendations trend for VRTX
Recommendations trend for VRTX


Analysts' buy bias toward VRTX suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, VRTX is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.